unknown
Stage
1
Investors
About
Wearlinq develops the eWave, a wireless continuous 6‑lead ECG wearable monitor, and associated clinician and patient software (LiveLinq and a mobile app) to transmit, review and report cardiac monitoring data; their device is described as FDA‑cleared on the company site. They also provide reporting services and 24/7 support for remote cardiac diagnostics.
Explore Wearlinq's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.